RMD stock forecast, quote, news & analysis

Key Takeaways

• ResMed (RMD) approaches Q3 fiscal 2026 earnings on April 30 with consensus expectations for 17.7% EPS (earnings per share) growth to $2.79 and 10% revenue increase to $1.42 billion.
• Analysts maintain overweight ratings, with recent initiations from JPMorgan and price target adjustments signaling confidence despite share price weakness.
• Recent trading sessions show pullback near 52-week lows, influenced by sector pressures and anticipation of results.
• Sleep apnea device demand remains structurally strong, but investors monitor GLP-1 drug impacts on obesity-related conditions.
• Tickeron's AI trading bots offer tools for navigating RMD's market dynamics across various strategies.

Current Market Snapshot

ResMed (RMD) stock has encountered downward pressure in recent weeks, hovering near the lower end of its 52-week range amid broader healthcare sector fluctuations and pre-earnings caution. Despite a year-to-date decline, the shares reflect resilience from underlying business momentum in sleep and respiratory care devices. Trading volumes have picked up in recent sessions, signaling heightened investor interest as the company nears its quarterly results disclosure. Market sentiment balances optimism around projected growth against concerns over competitive dynamics and macroeconomic headwinds affecting medical device demand. This positions RMD at a pivotal juncture for potential sentiment shifts.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of 25 top-performing AI trading bots from its library of 351 bots, designed for copy trading across stocks like RMD, ETFs, and crypto. These bots employ diverse strategies—including technical analysis, fundamental evaluation, and adaptations to low, medium, or high market volatility—catering to various timeframes and risk profiles. Selected by AI algorithms for suitability in current conditions, they deliver real-time signals via Signal Agents (basic), Virtual Agents (with risk management), or Brokerage Agents (live trading). While specific win rates and profit factors vary, the platform emphasizes bots with strong historical performance across thousands of tickers. Traders can explore these tools to complement manual analysis on volatile names like RMD, potentially enhancing decision-making in dynamic markets.

Recent Developments Driving RMD Price Action

ResMed (RMD), a leader in sleep apnea and respiratory devices, has seen its stock face recent weakness, declining modestly over the past 30 days despite positive analyst sentiment and upcoming earnings. The shares traded around $222 recently, down from higher levels earlier in the year, as investors weighed growth prospects against sector challenges.

Central to recent price dynamics is anticipation for Q3 fiscal 2026 results, due April 30, with Wall Street forecasting EPS of $2.79—a 17.7% year-over-year increase—and revenue of $1.42 billion, up 10%. This follows Q2's strong beat in January, where revenue rose 11% to $1.4 billion and non-GAAP EPS hit $2.81, aided by gross margin expansion to 61.8%. Analysts note a positive Earnings Surprise Prediction (ESP) of +0.39%, suggesting potential for another outperformance, which could catalyze a rebound.

Analyst activity has been robust, bolstering fundamentals amid the pullback. On April 27, KeyBanc maintained Overweight but trimmed its price target to $290 from $302. JPMorgan initiated Overweight coverage on April 15 with a favorable outlook. Earlier, Evercore ISI cut its target to $255 from $300 on April 13, while Citigroup held Buy on April 9. Consensus leans Overweight, with an average target near $290, implying upside potential. These updates reflect confidence in ResMed's mask demand and digital health investments, offsetting concerns.

Product innovation contributed positively, with ResMed announcing the Amalfi vs. CLA11 study on April 25, highlighting positive airway pressure (PAP) advancements for sleep apnea therapy. This underscores ongoing R&D in a market projected to grow amid rising diagnoses.

However, downward pressure stems from broader factors, including macroeconomic caution, supply chain echoes, and fears that GLP-1 weight-loss drugs could dampen obesity-linked sleep apnea prevalence. Philips' competitive resurgence adds scrutiny. Despite YTD softness, recent sessions showed modest gains, with volume spikes indicating positioning ahead of earnings. Overall, these elements have kept RMD volatile, trading 0.9% higher over 30 days but down short-term.

2026 Outlook and Key Factors to Monitor

As ResMed navigates 2026, investors should track several strategic themes in the expanding sleep apnea devices market, valued at billions and growing at 6-8% CAGR through the decade. Core growth drivers include rising OSA (obstructive sleep apnea) diagnoses—potentially affecting 77 million U.S. adults by 2050—aging demographics, and obesity trends fueling device and SaaS demand. ResMed's digital health ecosystem, including cloud-connected PAP devices and acquisitions like VirtuOx, positions it for out-of-hospital care expansion.

Opportunities lie in AI-enabled features like Smart Comfort and home testing innovations, enhancing therapy adherence. SaaS revenue from software for care providers offers recurring stability. However, risks include GLP-1 therapies potentially reducing PAP needs by addressing obesity roots, intensifying competition from Philips, and supply chain or currency pressures. Regulatory scrutiny on medical devices and reimbursement changes warrant attention. Macro factors like healthcare spending and economic cycles could influence volumes. Balanced monitoring of earnings execution, margin trends, and market penetration will shape ResMed's trajectory through the year.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations